Novartis AG ADR (NVS) - Total Assets
Based on the latest financial reports, Novartis AG ADR (NVS) holds total assets worth $118.53 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Novartis AG ADR investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Novartis AG ADR - Total Assets Trend (1998–2025)
This chart illustrates how Novartis AG ADR's total assets have evolved over time, based on quarterly financial data. Explore NVS long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Novartis AG ADR - Asset Composition Analysis
Current Asset Composition (December 2025)
Novartis AG ADR's total assets of $118.53 Billion consist of 26.4% current assets and 73.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $8.86 Billion | 9.9% |
| Accounts Receivable | $10.93 Billion | 9.5% |
| Inventory | $6.27 Billion | 5.4% |
| Property, Plant & Equipment | $12.35 Billion | 10.7% |
| Intangible Assets | $29.41 Billion | 25.5% |
| Goodwill | $25.57 Billion | 22.1% |
Asset Composition Trend (1998–2025)
This chart illustrates how Novartis AG ADR's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Novartis AG ADR worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Novartis AG ADR's current assets represent 26.4% of total assets in 2025, a decrease from 52.6% in 1998.
- Cash Position: Cash and equivalents constituted 9.9% of total assets in 2025, down from 12.6% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 47.0% of total assets, an increase from 10.0% in 1998.
- Asset Diversification: The largest asset category is intangible assets at 25.5% of total assets.
Novartis AG ADR Competitors by Total Assets
Key competitors of Novartis AG ADR based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
AstraZeneca PLC
F:ZEGA
|
Germany | €114.46 Billion |
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.02 Billion |
|
Novartis AG
SW:NOVN
|
Switzerland | CHF118.89 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$207.62 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $207.62 Billion |
|
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
SHE:301096
|
China | CN¥3.80 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
Novartis AG ADR - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.85 | 0.79 | 0.80 |
| Quick Ratio | 0.65 | 0.61 | 0.56 |
| Cash Ratio | 0.00 | 0.22 | 0.17 |
| Working Capital | $-4.77 Billion | $-6.51 Billion | $-5.83 Billion |
Novartis AG ADR - Advanced Valuation Insights
This section examines the relationship between Novartis AG ADR's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.39 |
| Latest Market Cap to Assets Ratio | 2.44 |
| Asset Growth Rate (YoY) | 13.0% |
| Total Assets | $115.57 Billion |
| Market Capitalization | $281.41 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Novartis AG ADR's assets at a significant premium (2.44x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Novartis AG ADR's assets grew by 13.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Novartis AG ADR (1998–2025)
The table below shows the annual total assets of Novartis AG ADR from 1998 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $115.57 Billion | +13.03% |
| 2024-12-31 | $102.25 Billion | +2.30% |
| 2023-12-31 | $99.94 Billion | -14.91% |
| 2022-12-31 | $117.45 Billion | -10.88% |
| 2021-12-31 | $131.79 Billion | -0.30% |
| 2020-12-31 | $132.19 Billion | +11.63% |
| 2019-12-31 | $118.41 Billion | -18.65% |
| 2018-12-31 | $145.56 Billion | +9.38% |
| 2017-12-31 | $133.08 Billion | +2.27% |
| 2016-12-31 | $130.12 Billion | -1.09% |
| 2015-12-31 | $131.56 Billion | +4.92% |
| 2014-12-31 | $125.39 Billion | -0.69% |
| 2013-12-31 | $126.25 Billion | +1.64% |
| 2012-12-31 | $124.22 Billion | +5.72% |
| 2011-12-31 | $117.50 Billion | -4.72% |
| 2010-12-31 | $123.32 Billion | +29.12% |
| 2009-12-31 | $95.50 Billion | +21.97% |
| 2008-12-31 | $78.30 Billion | +3.77% |
| 2007-12-31 | $75.45 Billion | +10.95% |
| 2006-12-31 | $68.01 Billion | +17.80% |
| 2005-12-31 | $57.73 Billion | +5.99% |
| 2004-12-31 | $54.47 Billion | +10.45% |
| 2003-12-31 | $49.32 Billion | +9.24% |
| 2002-12-31 | $45.14 Billion | +12.01% |
| 2001-12-31 | $40.30 Billion | +13.59% |
| 2000-12-31 | $35.48 Billion | -13.90% |
| 1999-12-31 | $41.21 Billion | +2.48% |
| 1998-12-31 | $40.21 Billion | -- |
About Novartis AG ADR
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic … Read more